STAT+: What Medicare Advantage enrollment could look like for next year
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
Category: government agencies
.jpg)
STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire
After his son Michael was diagnosed with a devastating, ultra-rare disease in 2019, Terry Pirovolakis…
STAT+: How powerful hospitals helped take R1 RCM private
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
Biden administration finalizes rules to ensure insurers pay for mental health care
The Biden administration on Monday announced it would finalize a highly anticipated proposal meant to…
A virus bodega, DNC takeaways, and free Covid tests
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
What’s in a drink? U.S. regulators consider new alcohol label, but health advocates want even more
If you twirl a bottle of alcohol and squint, you might see a text box…
STAT+: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England
LONDON — Patients in England with a rare blood disorder will now be able to…
STAT+: Lawmakers cast doubt on expert panel studying alcohol for 2025 dietary guidelines
Alcohol policy researchers are fuming over a letter sent by members of Congress last month,…
With Biden’s departure in sight, advocates seek to preserve gains of Cancer Moonshot
In President Biden’s address to the nation after dropping out of the election race, he…
Biden administration should push for addiction medication in recovery houses, groups say
The Biden administration isn’t doing enough to ensure people living in recovery housing have access…
STAT+: For-profit hospitals are getting a boost from a flood of patients
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
STAT+: Medicare and Medicaid struggles foreshadow a rocky health insurer earnings season
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry
The Food and Drug Administration’s power to make important regulatory decisions is in question after…
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Key health care topics to watch out for at the Biden-Trump debate
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
One firm, two conflicting takes on Alnylam’s HELIOS-B
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can JAK inhibitors bolster checkpoint inhibitors?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more
Rise and shine, everyone, another hot day is on the way. The forecast – at…
Lilly takes more actions against unapproved versions of Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novant Health calls off North Carolina hospital deal, giving a win to the FTC
Just two weeks ago, it appeared Novant Health was on the precipice of finalizing a…
Vanda Pharmaceuticals has another suitor
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Operation Warp Speed but for rare disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can AstraZeneca make good on its promise?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biotech’s most interesting fundraisings from the last week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
More tumult at BIO amid the company’s fourth CEO in four years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Maryland takes first steps to cap drug costs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly doubles down on radiopharma
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The public wants Medicare to cover obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Yet another big financing round in immunology
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The biotech news you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The latest government crackdowns on biotech you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
What about the company Vertex didn’t buy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Brazil’s plan for low-cost CAR-Ts
New biotech newsletter launching tomorrow. Don’t miss out. Good morning, everyone. Damian here with the…
Merck’s next big thing is (probably) on the way
New biotech newsletter launching this Thursday. Don’t miss out. Hello, everyone. Damian here with a look…
How will the Supreme Court’s mifepristone decision impact biopharma?
New biotech newsletter launching this Thursday. Don’t miss out. Hey there. Today, we discuss the…
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ibogaine, the psychedelic, unlikely to receive approval as opioid treatment, says top addiction researcher
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction,…